Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10969352 | Vaccine | 2011 | 9 Pages |
Abstract
This study compared immunogenicity and safety of DTaP5-IPV-Hib to DTaP3-IPV/Hib coadministered with PCV7 at 2, 3, and 4 months (primary series) and a fourth-dose booster at 12-18 months of age. Seroprotection rates for DTaP5-IPV-Hib were high (noninferior to DTaP3-IPV/Hib for the primary series) for antigens common to both vaccines and PCV7 antigens. Geometric mean concentration (GMC) for Hib antibodies were higher in the DTaP5-IPV-Hib group than the DTaP3-IPV/Hib group after the primary series and booster dose; GMCs or titers for other antigens were generally similar between groups after the primary series and booster dose. Safety profiles were similar between groups.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Emmanuel Grimprel, Jacek Wysocki, Florence Boisnard, Stéphane Thomas, Grace Mwawasi, Donna Reynolds,